Startup Miist develops inhaler to help smokers quit and relieve migraines
Dalton Signor founded Miist Therapeutics to create a fast-acting inhaler for smoking cessation and migraines. The device delivers medication directly to the lungs, providing relief in just two minutes, significantly faster than traditional methods. Miist recently secured $7 million in seed funding after promising results from its Phase I trial, which showed a 92% reduction in cravings among smokers. The inhaler mimics vaping behavior, potentially aiding the psychological aspects of quitting. The company is preparing for a Phase II trial for its smoking cessation product and is also testing migraine medications. Miist aims to expand its inhaler technology for other health conditions in the future.